FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1902-1903 April 29, 2004 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

More than 25 million people, most of whom are menopausal or elderly women, have a progressive loss of bone mass, which increases their susceptibility to fracture. The increasing prevalence and tremendous costs of this disorder underscore the importance of developing new treatments. Because the pathogenesis of osteoporosis is multifactorial — bone mass is influenced by physical activity, nutrition, and genetic factors — devising new therapeutics is a challenge. The recent findings of Klein et al. therefore come as welcome news: the authors identified an enzyme, 12/15-lipoxygenase, that contributes to natural variations in bone mass and skeletal development in mice, and . . . [Full Text of this Article]

Source Information

From Brigham and Women's Hospital and Harvard University, Boston.

This article has been cited by other articles:

• Kondo, H., Nifuji, A., Takeda, S., Ezura, Y., Rittling, S. R., Denhardt, D. T., Nakashima, K., Karsenty, G., Noda, M. (2005). Unloading Induces Osteoblastic Cell Suppression and Osteoclastic Cell Activation to Lead to Bone Loss via Sympathetic Nervous System. J. Biol. Chem. 280: 30192-30200 [Abstract] [Full Text]